Ikena Oncology, Inc. (IKNA)
US — Healthcare Sector
Automate Your Wheel Strategy on IKNA
With Tiblio's Option Bot, you can configure your own wheel strategy including IKNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IKNA
- Rev/Share 0.0
- Book/Share 2.4504
- PB 0.5591
- Debt/Equity 0.0559
- CurrentRatio 13.3059
- ROIC -0.4048
- MktCap 66113597.0
- FreeCF/Share -0.7929
- PFCF -1.7279
- PE -1.5852
- Debt/Assets 0.0505
- DivYield 0
- ROE -0.32
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Ikena Oncology, Inc. (IKNA)
- IPO Date 2021-03-26
- Website https://ikenaoncology.com
- Industry Biotechnology
- CEO Dr. Mark Manfredi Ph.D.
- Employees 10
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.